SEC Form 4 · accession 0001415889-17-000018
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John David Hansen
Officer — PRESIDENT AND CEO · Director
Period of report
Jan 1, 2017
Accepted (ET)
Jan 3, 2017 · 8:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $3.38 | Jan 1, 2017 | A | 63,400 | A | — | Jan 1, 2027 | Common Stock | 63,400 | 63,400 | D |
Explanation of responses
- F1Such Options shall vest in equal annual installments over a three year period.